Innovative Medicine
-
-
FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events
XARELTO® Has the Broadest Indication Profile of Any New Oral Anticoagulant -
New One-Year Phase 3 Study Results Show Anti-Tnf SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
Data Demonstrate Remission and Mucosal Healing with SIMPONI Maintenance Therapy -
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® Treatment
STELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine -
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study -
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
Orally Administered Investigational Therapy Expands Global Immunology Portfolio -
New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival -
Janssen Connected Health Challenge Europe 2012 Launching To Spur Healthcare Innovation
Janssen Connected Health Challenge seeks transformational care ideas and offers awards totalling €30,000 to develop winning solutions -
DACOGEN® Approved In the European Union for the Treatment of Acute Myeloid Leukaemia
New treatment offers clinically significant benefit for patients